Calcium-channel blockers
Isradipine and other L-type calcium-channel blockers — Cav1.3 hypothesis and STEADY-PD3.
State of the art
No update yet for Calcium-channel blockers. An update is a standalone state-of-the-art for the topic — what someone with Parkinson's needs to know about where this approach stands today.
No reader summaries on this topic yet.